Constellation Brands beats estimates as beer gains offset softer demand

Impact · against what's priced in

The update is marginally negative for STZ as a lowered margin guidance confirms current price skepticism regarding profitability, while beer volume declines remain consistent with existing market fears. Genflow Biosciences' data release provides a neutral to positive update on its SIRT6 therapy pipeline.

STZ−0.10

Already priced in

The price assumes

A continued decline in beer volumes

Beer depletions fell 0.6% this quarter, which aligns with the market's current assumption of continued volume declines and recent dollar takeaways.

What STZ's price assumes · Sep 13

• STZ▲900%
• guidance▲8%
• earnings
• GENF
• beer
• beverages
• consumer goods
• share buybacks